Small Molecules, Big Impact: The Fascinating History of Peptides 

EDUCATIONAL DISCLAIMER

This content is for informational purposes only and does not constitute medical advice. Peptide therapy should always be pursued under the guidance of a qualified, licensed healthcare provider. Individual results vary.

The history of therapeutic peptides is a story that spans more than a century. From the first amino acid isolated in a French laboratory to the blockbuster peptides reshaping modern medicine, this journey is one of the most remarkable in science. It involves brilliant chemists, happy accidents, Nobel Prizes, and even a few venomous lizards. It is the story of how scientists learned to speak the body’s own chemical language, decoding the microscopic signals that keep us alive and healthy. From the earliest days of extracting compounds from animal tissue to the modern era of artificial intelligence and computer aided drug design, the evolution of peptide science is a testament to human ingenuity. 

To truly appreciate the power of peptide therapy today, we have to look back to the early 19th century and the key milestones that brought these microscopic messengers out of the lab and into the clinic. 

Wait… What’s a Peptide, Exactly? A peptide is simply a short chain of amino acids linked together. You can think of them as tiny proteins. While proteins might have hundreds of amino acids folded into complex three-dimensional shapes, peptides usually have between two and 50 amino acids. They act as messengers in the body, traveling through the bloodstream to tell cells what to do. Because they are smaller than proteins, they can often penetrate tissues more easily, making them ideal candidates for medical treatments. 

Pre 20th Century: The Foundations of Chemistry

Before scientists could build peptides, they had to figure out what they were made of. The story begins in the early 1800s, a time when chemistry was still finding its footing as a modern science. Researchers were obsessed with understanding the fundamental building blocks of life, leading to the discovery of amino acids. 

In 1820, a French chemist named Henri Braconnot was experimenting with gelatin, trying to understand its composition. By boiling it with sulfuric acid, he isolated a sweet tasting substance. He had just discovered glycine, the simplest of all amino acids. This was a monumental moment. Over the next several decades, chemists across Europe slowly identified the other amino acids that make up the human body, piecing together the alphabet of life one letter at a time. 

But identifying the letters was only the first step. How did these individual building blocks connect to form larger structures? That question remained a mystery until the turn of the 20th century, when a brilliant German chemist named Emil Fischer entered the scene. 

“Few scientists acquainted with the chemistry of biological systems at the molecular level can avoid being inspired.”

Donald Cram, Nobel Laureate in Chemistry 

Emil Fischer is widely considered the father of peptide chemistry. In 1902, he proposed a radical new idea: that amino acids link together in long chains, connecting head to tail in a specific sequence. He coined the term “peptide bond” to describe this connection. To prove his theory, Fischer did not just write about it, he actually managed to synthesize the first artificial dipeptide (two amino acids linked together) in his laboratory. His groundbreaking work laid the conceptual foundation for all peptide drug development to come, earning him the Nobel Prize in Chemistry in 1902.¹ 

Fischer’s discovery ignited a century of innovation. He proved that the complex molecules of life were not magical or beyond human comprehension. They were chemical structures that could be understood, mapped, and eventually, recreated. 

Early 20th Century: Breakthroughs in Medicine

Understanding what peptides were was one thing. Using them as medicine was another entirely. The transition from theoretical chemistry to life saving medicine happened in the early 1920s, and it remains one of the most famous and impactful stories in medical history. 

At the time, a diagnosis of Type 1 diabetes was essentially a death sentence. Patients wasted away as their bodies became unable to process sugar.

But a Canadian surgeon named Frederick Banting and his assistant Charles Best had an idea. Working in a hot, cramped laboratory at the University of Toronto in the summer of 1921, they managed to isolate a mysterious substance from the pancreases of dogs. They called it insulin. 

In January 1922, a 14-year-old boy named Leonard Thompson became the first person to receive an insulin injection. He was near death, slipping in and out of a diabetic coma, and weighed just 65 pounds. The injection worked. His blood sugar dropped, his strength returned, and he survived. The first true peptide therapy was born. It was a miracle that reversed the diabetes death sentence overnight, changing the course of medical history forever.² 

Interesting Fact: Because early insulin was extracted from the pancreases of cows and pigs, it took a massive amount of animal tissue to produce a single dose, a logistical challenge that made the case for finding a way to synthesize peptides artificially.   

While insulin was an undeniable triumph, relying on animal sources was not sustainable. It was expensive, inefficient, and sometimes caused allergic reactions in patients. Scientists needed a way to build these hormones from scratch in a laboratory. The next major milestone arrived in 1953 when American biochemist Vincent du Vigneaud successfully synthesized oxytocin, a peptide hormone responsible for inducing labor and lactation. 

This was the first time a peptide hormone had been created entirely in a laboratory, proving that humans could create these complex biological messengers without relying on animal extracts. Du Vigneaud’s meticulous work demonstrated that synthetic peptides could function exactly like their natural counterparts. He was awarded the Nobel Prize in Chemistry in 1955 for his incredible achievement.³ 

Mid 20th Century: The Synthesis Revolution

By the late 1950s, scientists knew how to synthesize peptides, but the process was agonizingly slow and incredibly frustrating. Building a peptide chain meant adding one amino acid at a time in a liquid solution, purifying the entire mixture after every single addition, and repeating the process over and over. It could take months of painstaking labor to build a single short peptide.

That all changed in 1959 thanks to an American biochemist named R.B. Merrifield. He recognized that the purification steps were the bottleneck, so he invented a radically new technique called Solid Phase Peptide Synthesis (SPPS). He attached the first amino acid to a solid microscopic bead of polystyrene. This anchored the growing peptide chain in place, allowing scientists to simply wash away the chemical impurities between each step without losing the peptide itself.⁴ 

Merrifield’s invention revolutionized the speed and efficiency of peptide drug development. What used to take months could now be done in days, and eventually, hours. It automated the process of peptide creation, opening the floodgates for researchers around the world to experiment with new sequences. The technique was so transformative that he was awarded the Nobel Prize in Chemistry in 1984. 

“The development of solid phase peptide synthesis by Bruce Merrifield is one of the most important methodological developments in the history of chemistry.” 

The Nobel Prize Committee, 1984 

Around the same time another massive milestone was achieved on the other side of the world. In 1965, after years of intense effort and collaboration, a team of Chinese scientists successfully synthesized biologically active bovine insulin. It was the first time a protein of that size and complexity had been created artificially. This monumental achievement cemented China’s position as a world leader in therapeutic peptide research and proved that even the most complex peptide structures could be built from scratch.⁵ 

Late 20th Century: Nature’s Hidden Pharmacy

With synthesis techniques mastered, the 1970s and 1980s saw an explosion in peptide discovery. But scientists were not just looking inward at human biology, they were looking outward at nature’s most extreme environments. The natural world had already done the hard work,   producing peptide structures precisely tuned for very specific biological purposes. 

Researchers began discovering highly potent, bioactive peptides in the venoms of snakes, scorpions, spiders, and marine cone snails. Because venom must act quickly and specifically to paralyze or kill prey, venom peptides are incredibly precise. They target specific receptors in the nervous system with pinpoint accuracy. This precision makes them excellent templates for targeted drugs, particularly for pain management and neurological conditions. 

The 1980s also brought the DNA revolution. Instead of building peptides chemically, scientists learned to program bacteria and yeast to produce human peptides for them. By inserting human genes into these microorganisms, they turned them into microscopic peptide factories. This allowed for the mass production of human insulin, completely replacing the need for animal sources and making the drug safer, cheaper, and more accessible worldwide. 

Global Timeline of Peptide Innovation

The Modern Era: Therapeutic Advancements

While early breakthroughs often occurred in isolated laboratories, the modern era of peptide science and peptide pharmacology is a deeply international endeavor. Organizations like the Peptide Institute in Osaka, Japan, established in the 1970s, became critical hubs for commercial peptide manufacturing. Meanwhile, pharmaceutical giants in Denmark and Switzerland drove the commercialization of metabolic and immunosuppressive peptides, proving that turning a fragile molecule into a viable drug requires a global network of collaboration. 

Despite all the benefits that researchers had observed in the lab, peptide-based therapeutics always faced one major hurdle: the human body is very efficient at breaking them down. Peptides are fragile. If you swallow a peptide, your stomach acids and digestive enzymes break it down just like a piece of steak, long before it can reach your bloodstream. Even if injected, enzymes in the blood often clear natural peptides from the system in a matter of minutes. 

Peptide therapy research in the 1990s and 2000s was defined by scientists finding clever ways to protect peptides and extend their half life. They developed strategies to shield the molecules, such as attaching them to fatty acids (lipidation) or stapling their structures together so they could survive longer in the harsh environment of the human body. Monitoring peptide therapy side effects in early clinical trials was also a central focus, helping researchers understand which modifications were safe and which introduced new risks. This critical work paved the way for the most significant shift in modern metabolic medicine: the GLP-1 era. 

Glucagon-like peptide-1 (GLP-1) is a naturally occurring hormone that regulates blood sugar and appetite. But natural human GLP-1 is incredibly fragile, lasting only about two minutes in the body before being destroyed by enzymes. The breakthrough came from a highly unlikely source: the venom of the Gila monster, a slow moving, brightly colored lizard native to the American Southwest. 

Researchers discovered that a peptide in the lizard’s venom, called exendin-4, functioned almost exactly like human GLP-1, but it was highly resistant to degradation. It lasted much longer in the bloodstream, providing sustained blood sugar control.⁷ 

This unexpected discovery led to the development of a new class of long acting GLP-1 receptor agonists. By tweaking the amino acid sequence and adding protective fatty chains, scientists created drugs like semaglutide and tirzepatide that only need to be injected once a week. Therapeutic peptides have completely redefined the treatment of type 2 diabetes and obesity, becoming some of the most prescribed medications in the world. Growth hormone peptides followed a similar path, with researchers engineering longer acting versions of what our bodies produce naturally to address age-related hormone decline. 

Today the FDA has approved over 100 peptide drugs, and the field of peptide therapy research is expanding rapidly. The tools available to modern researchers are vastly more sophisticated than those used by early pioneers like Emil Fischer or R.B. Merrifield. Artificial intelligence and machine learning are now being used to design novel peptides from scratch, predicting how they will behave, and interact with human cells before they are ever synthesized in a physical lab. This approach is dramatically accelerating the drug discovery process. 

Researchers are also investigating new methods for oral delivery. For decades, a major goal in peptide research has been developing compounds that can survive the stomach and enter the bloodstream without being destroyed. New formulation technologies, absorption enhancers, and protective coatings are finally making this a reality. Oral peptides will eliminate the need for injections, making these therapies far more convenient and accessible to patients worldwide. 

Beyond metabolic health, the applications for peptides are expanding rapidly. The peptide therapy benefits seen in metabolic disease are now being explored in oncology, neurology, and infectious disease. Scientists are leveraging antimicrobial peptides to combat multidrug resistant bacteria, offering a potential solution to the growing crisis of antibiotic resistance. They’re also developing personalized cancer vaccines using neoantigen based peptides, tailored to the specific genetic mutations of each patient’s tumor, training the immune system to attack the cancer with precision. 

From a sweet tasting crystal extracted from gelatin in 1820 to the precision engineered molecules of today, the history of peptides is a testament to human curiosity, perseverance, and innovation. As peptide therapy side effects have become better understood and managed, patient access and physician confidence have grown significantly. As technology continues to advance, the story is really just beginning.

Scientific References 

1.  Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. 2021;20(4):309-326. doi:10.1038/s41573-020-00115-8 

2.  Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. 1922;12(3):141-146. 

3.  du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. 1953;75(18):4879-4880. 

4.  Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. 1963;85(14):2149-2154. 

5.  Kung YT, Du YC, Huang WT, et al. Total synthesis of crystalline bovine insulin. 1965;14(11):1710-1716. 

6.  Borel JF, Kis ZL. The discovery and development of cyclosporine (Sandimmune). 1991;23(2):1867-1874. PMID:2053181 

7.  Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. 1992;267(11):7402-7405. doi:10.1016/S0021-9258(18)42531-8 

© 2026 PeptideMatch.io. All Rights Reserved. This educational content is the exclusive intellectual property of PeptideMatch.io. Reproduction, distribution, republication, or transmission of this material, in whole or in part, in any form or by any means, is strictly prohibited without the prior written consent of PeptideMatch.io. For licensing or reprint inquiries, please contact content@peptidematch.io .